Cellular mechanism(s) regulating atriopeptin secretion and processing by the atrial myocyte are currently unknown. Osmotic stretch of isolated atrial myocytes as well as potassium chloride depolarization were potent stimuli of atriopeptin secretion. Release was potentiated by buffering either extracellular calcium with EGTA or intracellular calcium with the intracellular chelator, BAPTA AM. Atrial release of atriopeptin was inhibited after administration of ionomycin which elevates intracellular calcium. Fetal or early neonatal ventricular myocytes actively synthesize atriopeptin. Atriopeptin secretion by ventricular myocytes was also markedly potentiated by osmotic stretch as well as KCI depolarization. Only the 126 amino acid prohormone was secreted by the stretch-stimulated atrial and ventricular myocyte. These data suggest that stretch of the myocyte plasma membrane is a major stimulus for atriopeptin secretion and that atriopeptin secretion is not stimulated by raising intracellular calcium and appears to be negatively modulated by this cation. Like the atrial myocyte, the ventricular myocyte possesses the cellular mechanism(s) necessary to secrete atriopeptin by a regulated mechanism.
Introduction
The heart has recently been demonstrated to play an important role in intravascular volume homeostasis. Mammalian atrial myocytes synthesize, store, and release a peptide hormone, atriopeptin (AP),' which has potent natriuretic, diuretic, and vasodilating activity (1) (2) (3) (4) . Thus, the heart is not only a pump but also an endocrine organ. Distension of the atrial chamber in vitro in isolated perfused hearts or in vivo stimulates release of AP (5) (6) (7) (8) ; however, the precise cellular mechanism(s) coupling mechanical distension to hormonal release remains unresolved. 1 . Abbreviations used in this paper: AP, atriopeptin; APir, atriopeptin immunoreactivity; AP28, atriopeptin-28; LDH, lactate dehydrogenase; pro-AP, prohormone atriopeptin.
By analogy to other secretory systems (9) it has been postulated that a rise in intracellular calcium (Ca"2) is a stimulus for AP release. This hypothesis is supported by the demonstration that AP release from the isolated rat heart is moderately enhanced by the Ca"2 ionophore A23187 (10) or the Ca"2 channel agonist BAY K8644 (11) . The ventricular myocardium possesses trace amounts of AP immunoreactivity (APir) when compared with atrial tissue (12) (13) (14) (15) . Recently it has been demonstrated that mRNA coding for prepro-AP is present in both adult rat and human ventricle as well as newborn rat ventricular myocyte cell cultures, but at lower concentrations than atrial tissue or cultures (15) . The abundance of AP mRNA and APir is increased in hypertrophied ventricles (12) , ventricles from spontaneously hypertensive rats (13) , and fetal and neonatal rat ventricles (14) . In hypertrophied ventricles, the total mass of AP mRNA approaches one-third the amount present in the atrium (12) . Pulse-chase experiments in cultured myocytes resulted in the suggestion that atrial myocytes secrete AP by a regulated process but that ventricular myocytes release the peptide constitutively (16) . Unfortunately, these studies were restricted to the basal, i.e., unstimulated, release of AP. The physiological significance of ventricular AP and whether AP release in this tissue responds to physiological stimuli have yet to be determined.
The 126 amino acid AP prohormone is synthesized and stored in atrial-specific granules. In vivo, atrial stretch results in the rapid release and instant enzymatic cleavage of the prohormone to yield the 28 amino acid carboxy-terminal fragment (AP28), which has been demonstrated to be the circulating hormone (17) . Cultured atrial myocytes release predominantly the 126 amino acid prohormone (18, 19) in the basal, nonstimulated state, whereas the isolated perfused heart releases only AP28 and no intact prohormone. It therefore appears that the myocardium (i.e., nonmyocytic cardiac cells) but not the myocyte has this enzymatic capacity for prohormone cleavage. It is possible, however, that pro-AP processing by cultured atrial myocytes has not been observed because the intracellular route of constitutively secreted pro-AP physically bypasses the processing enzyme and that stimulated (i.e., granular) secretion of AP may unmask myocytic, pro-AP processing.
To elucidate the cellular mechanism responsible for AP secretion and processing, we 
Results
To develop an experimental model of stretch-induced AP release from myocyte suspensions, we reasoned that if the sarcolemma is the site of mechano-chemical transduction, then any manipulation that increases cell volume should "stretch" the cell membrane and thus result in AP release. Increases in cell volume (i.e., stretch) were produced by exchanging the isotonic suspension solution for hypotonic solutions. Roos (23) has demonstrated that the isolated myocyte undergoes -50% of the predicted volume change upon reduction of extracellular osmolarity (300 to 200 mosM).
Rat neonatal atrial myocyte suspensions released AP as an inverse function of solution osmolarity (Fig. 1) slight reductions in AP release were observed. It was necessary, however, to confirm that peptide release was not a result of cell death or hypotonic lysis. The activity of LDH released into solutions during hypotonic stimulation was measured and taken to be an index of cell damage. As illustrated in Fig. 1 , no significant relationship existed between LDH activity and solution osmolarity. The proportion of LDH in the cellular media as a function of total cellular LDH was determined to be < 5% in all experimental conditions, further demonstrating a > 95% viability of our suspended cells. We therefore conclude that hypotonic swelling (stretch) is a specific stimulus for AP release without cell lysis.
The molecular form of AP released by osmotic stretch was analyzed by HPLC. The immunoreactive AP released into 200 mosM solution comigrated at the position of the 126 amino acid, AP prohormone standard (data not shown), which suggests that the processing enzyme is not associated with the isolated atrial myocyte.
To understand the biochemical cellular processes involved in stretch-stimulated AP release, we evaluated the importance of cytosolic Ca"2 as a potential intracellular messenger. As cardiac myocytes have a large voltage-activated Ca"2 conductance, we evaluated whether cellular depolarization with KC1 results in AP release as a direct result of Ca+2 influx through voltage-activated channels. KCl (25-65 mM) produced a dose-dependent release of AP (Fig. 2) . Examination of the measured AP release as a function of the membrane potential, predicted from the Nernst equation for potassium, revealed a marked voltage dependence of the release process. Interestingly, the potential range over which AP release rises most rapidly is remarkably close to the potential at which the slow inward Ca+2 current begins to activate (24).
If, indeed, Ca+2 stimulates AP release, we hypothesized that both sarcolemmal stretch and depolarization with KCl should similarly produce increases in intracellular Ca 2. Intra- ; 19 All values are normal- (25) . BAPTA AM has been used effectively to block lectin-stimulated mast cell degranulation, which has been demonstrated to be a Ca+2-dependent process (25) . Atrial myocytes preincubated with BAPTA AM for 1 h exhibited a 34% increase in basal AP release and a greater response to both KCl depolarization and osmotic stretch when compared with cells not exposed to the chelator (Table I) elevated diastolic myocardial pressures, we hypothesized that stretch of the ventricular myocyte sarcolemma would stimulate AP secretion if regulated secretory mechanism(s) existed and were functional in these cells. Neonatal ventricular myocytes released AP as an inverse function ofsolution osmolarity (Fig. 3 A) . Ventricular myocytes suspended in 200 mosM media released threefold the amount of AP released into isotonic (300 mosM) solution. This amount of AP release represented -6% of the total cellular AP. To further evaluate AP secretion in response to a second potential ventricular AP secretagogue, we exposed neonatal ventricular myocytes to two concentrations of KCI that were effective in stimulating atrial AP release. As seen in Fig. 3 B, depolarization of ventricular myocytes with KCl produced a dose-dependent release of AP into the cellular media. We conclude from these data that neonatal ventricular myocytes, similar to atrial myocytes, release AP in response to sarcolemmal stretch and KCI depolarization, therefore demonstrating the potential of these cells to release AP in a regulated, nonconstitutive manner.
Discussion
The model of plasma membrane stretch used in these studies results from the initial swelling ofthe cells in hypotonic media. Therefore, plasma membrane stretch is a result ofintracellular forces, different from the mechanism of stretch in the working heart. However, recently it has been demonstrated that hypotonic swelling of isolated cells results in the opening of cationselective Ca+2-permeable channels (26). These are the same channels that have been previously shown to respond to mechanical stretch (27 (34) . Furthermore, it is indeed possible that glucocorticoids can pharmacologically induce the expression of a proteolytic enzyme that processes AP prohormone in cultured myocytes; however, the physiological significance of this has yet to be determined. We conclude that another cell type within the myocardium is required for the generation of the 28 amino acid peptide.
